For the year ending 2025-12-31, IPSC made $109,164K in revenue. -$9,874K in net income. Net profit margin of -9.05%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Collaboration revenue | 109,164 | |||
| Research and development | 95,667 | |||
| General and administrative | 24,003 | |||
| Impairment of long-lived assets | 6,763 | |||
| Total operating expenses | 126,433 | |||
| Loss from operations | -17,269 | |||
| Interest income | 7,346 | |||
| Other income | 275 | |||
| Total other income | 7,621 | |||
| Loss before provision for income taxes | -9,648 | |||
| (benefit) provision for income taxes | -68 | |||
| Net loss | -9,580 | |||
| Unrealized gain (loss) on investments | -294 | |||
| Comprehensive loss | -9,874 | |||
| Basic EPS | -0.14 | |||
| Diluted EPS | -0.14 | |||
| Basic Average Shares | 86,556,515 | |||
| Diluted Average Shares | 86,556,515 | |||
Century Therapeutics, Inc. (IPSC)
Century Therapeutics, Inc. (IPSC)